BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36405757)

  • 1. NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model.
    Hu Y; Paris S; Bertolet G; Barsoumian HB; Wang Q; Da Silva J; Patel NB; Nguyen N; Doss DJ; Huang A; Hsu E; Leyton CSK; Voss TA; Masrorpour F; Leuschner C; Pietz JT; Puebla-Osorio N; Gandhi S; Nguyen QN; Wang J; Cortez MA; Welsh JW
    Front Immunol; 2022; 13():1022011. PubMed ID: 36405757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model.
    Hu Y; Paris S; Barsoumian H; Abana CO; He K; Sezen D; Wasley M; Masrorpour F; Chen D; Yang L; Dunn JD; Gandhi S; Nguyen QN; Cortez MA; Welsh JW
    J Nanobiotechnology; 2021 Dec; 19(1):416. PubMed ID: 34895262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer.
    Hu Y; Paris S; Bertolet G; Barsoumian HB; He K; Sezen D; Chen D; Wasley M; Silva JD; Mitchell JA; Voss TA; Masrorpour F; Leyton CK; Yang L; Leuschner C; Puebla-Osorio N; Gandhi S; Nguyen QN; Cortez MA; Welsh JW
    J Nanobiotechnology; 2022 Sep; 20(1):417. PubMed ID: 36123677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects.
    Hu Y; Paris S; Barsoumian H; Abana CO; He K; Wasley M; Younes AI; Masrorpour F; Chen D; Yang L; Dunn JD; Zhang J; Gandhi S; Nguyen QN; Cortez MA; Welsh J
    Int J Radiat Oncol Biol Phys; 2021 Nov; 111(3):647-657. PubMed ID: 34242713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy.
    Hu Y; Revenko A; Barsoumian H; Bertolet G; Fowlkes NW; Maazi H; Green MM; He K; Sezen D; Voss TA; Leyton CSK; Masrorpour F; Rafiq Z; Puebla-Osorio N; Leuschner C; MacLeod R; Cortez MA; Welsh JW
    J Exp Clin Cancer Res; 2024 Mar; 43(1):70. PubMed ID: 38443968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.
    Niknam S; Barsoumian HB; Schoenhals JE; Jackson HL; Yanamandra N; Caetano MS; Li A; Younes AI; Cadena A; Cushman TR; Chang JY; Nguyen QN; Gomez DR; Diab A; Heymach JV; Hwu P; Cortez MA; Welsh JW
    Clin Cancer Res; 2018 Nov; 24(22):5735-5743. PubMed ID: 29784675
    [No Abstract]   [Full Text] [Related]  

  • 7. Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection.
    Hu Y; Paris S; Sahoo N; Bertolet G; Wang Q; Wang Q; Barsoumian HB; Da Silva J; Huang A; Doss DJ; Pollock DP; Hsu E; Selene N; Leyton CSK; Voss TA; Masrorpour F; Ganjoo S; Leuschner C; Pietz JT; Puebla-Osorio N; Gandhi S; Nguyen QN; Wang J; Cortez MA; Welsh JW
    JCI Insight; 2023 Jun; 8(12):. PubMed ID: 37345658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
    Vijayakumar G; Palese P; Goff PH
    EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy-activated NBTXR3 nanoparticles promote ferroptosis through induction of lysosomal membrane permeabilization.
    Da Silva J; Bienassis C; Schmitt P; Berjaud C; Guedj M; Paris S
    J Exp Clin Cancer Res; 2024 Jan; 43(1):11. PubMed ID: 38173001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.
    Schoenhals JE; Cushman TR; Barsoumian HB; Li A; Cadena AP; Niknam S; Younes AI; Caetano MDS; Cortez MA; Welsh JW
    Front Immunol; 2018; 9():2170. PubMed ID: 30294332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.
    Caetano MS; Younes AI; Barsoumian HB; Quigley M; Menon H; Gao C; Spires T; Reilly TP; Cadena AP; Cushman TR; Schoenhals JE; Li A; Nguyen QN; Cortez MA; Welsh JW
    Clin Cancer Res; 2019 Dec; 25(24):7576-7584. PubMed ID: 31540976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials.
    Chen D; Menon H; Verma V; Guo C; Ramapriyan R; Barsoumian H; Younes A; Hu Y; Wasley M; Cortez MA; Welsh J
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31996395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer.
    Ji D; Song C; Li Y; Xia J; Wu Y; Jia J; Cui X; Yu S; Gu J
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33106387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer.
    Yin L; Xue J; Li R; Zhou L; Deng L; Chen L; Zhang Y; Li Y; Zhang X; Xiu W; Tong R; Gong Y; Huang M; Xu Y; Zhu J; Yu M; Li M; Lan J; Wang J; Mo X; Wei Y; Niedermann G; Lu Y
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):212-224. PubMed ID: 32417411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors.
    Kaptein P; Jacoberger-Foissac C; Dimitriadis P; Voabil P; de Bruijn M; Brokamp S; Reijers I; Versluis J; Nallan G; Triscott H; McDonald E; Tay J; Long GV; Blank CU; Thommen DS; Teng MWL
    Sci Transl Med; 2022 Apr; 14(642):eabj9779. PubMed ID: 35476594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NBTXR3 Radiotherapy-Activated Functionalized Hafnium Oxide Nanoparticles Show Efficient Antitumor Effects Across a Large Panel of Human Cancer Models.
    Zhang P; Marill J; Darmon A; Mohamed Anesary N; Lu B; Paris S
    Int J Nanomedicine; 2021; 16():2761-2773. PubMed ID: 33880022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy-Activated Hafnium Oxide Nanoparticles Produce Abscopal Effect in a Mouse Colorectal Cancer Model.
    Zhang P; Darmon A; Marill J; Mohamed Anesary N; Paris S
    Int J Nanomedicine; 2020; 15():3843-3850. PubMed ID: 32581534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
    Zhang X; Niedermann G
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.
    Hossain DMS; Javaid S; Cai M; Zhang C; Sawant A; Hinton M; Sathe M; Grein J; Blumenschein W; Pinheiro EM; Chackerian A
    J Clin Invest; 2018 Feb; 128(2):644-654. PubMed ID: 29337311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
    Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
    Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.